Accelerating the Rate of Improvement in Care Cystic fibrosis (CF) is an inherited chronic disease that affects the lungs and digestive system. It is estimated by the CF Foundation that 30,000 children and adults in the United States (70,000 worldwide) are afflicted with the disease.
A defective gene and the protein it produces lead to unusually thick, sticky mucus that clogs the lungs and obstructs the pancreas. While advances in research and medical treatments have extended the life expectancy for people with CF into their 30s and 40s, many face a premature death from battling a life time of bacterial lung infections.
The Dartmouth Institute and the Cystic Fibrosis Foundation are long-standing partners. The CF Foundation is the world’s leader in the search for a cure, drug discovery, and setting the standards for CF care. Working closely with interdisciplinary professionals at the 110 CF Foundation-accredited care centers, The Dartmouth Institute supports outcomes research and improving leadership and care delivery using the Dartmouth Clinical Microsystems framework. The CF Foundation’s national initiative, Accelerating the Rate of Improvement in CF Care, guides the work of this partnership through 5 key strategies:
As The Dartmouth Institute helps advance CF clinical care, colleagues at the Geisel School of Medicine at Dartmouth conduct clinical trials and basic science research to fuel the CF Foundation’s mission to find a cure and discover new treatments.